Modern lipid-, carbohydrate-, and peptide-based delivery systems for peptide, vaccine, and gene products

Medicinal Research Reviews

Volumn 31, Issue 4, 2011, Pages 520-547

  Simerska, Pavla ^a   Moyle, Peter M ^a   Toth, Istvan ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Delivery; Gene; Lipid; Peptide; Vaccine

Indexed keywords

CELL PENETRATING PEPTIDE; DENDRIMER; DRUG CARRIER; EPITOPE; GENE PRODUCT; GLYCOLIPID; PEPTIDE VACCINE; POLYCATION;

ARTICLE; DRUG ABSORPTION; DRUG METABOLISM; DRUG STABILITY; DRUG TRANSPORT; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSCRIPTION; GLYCOSYLATION; HUMAN; MEMBRANE PERMEABILITY;

ANIMALS; CARBOHYDRATES; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; LIPIDS; PEPTIDES; VACCINES;

EID: 79959565855     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.20191     Document Type: Article

References (186)

1. State of the world's vaccines and immunization. Geneva, Switzerland: World Health Organization; 2003.
2. Jiskoot W, Kersten GFA, Mastrobattista E. Vaccines. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology: Fundamentals and applications. 3rd edition. London: Taylor & Francis; 2007.
3. Mittal SK, HogenEsch H, Park K. Vaccines and other immunological products. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. 3rd edition. London: Taylor & Francis; 2007.
4. Moore ML, Grant GA. Peptide design considerations. In: Grant GA, editor. Synthetic peptides, a user's guide. 2nd edition. New York, NY: Oxford University Press; 2002. pp 10-92.
5. Schild H, Rammensee H-G. Peptide based vaccines. In: Kaufmann SHE, editor. Concepts in vaccine development. Berlin, Germany: Walter de Gruyter & Co; 1996. pp 303-325.
6. Wiesmuller KH, Fleckenstein B, Jung G. Peptide vaccines and peptide libraries. Biol Chem 2001;382:571-579.
7. Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 2007;6:404-414.
8. Adessi C, Soto C. Converting a peptide into a drug: Strategies to improve stability and bioavailability. Curr Med Chem 2002;9:963-978.
9. Gentilucci L, Tolomelli A, Squassabia F. Peptides and peptidomimetics in medicine, surgery and biotechnology. Curr Med Chem 2006;13:2449-2466.
10. Jiang S, Li Z, Ding K, Roller PP. Recent progress of synthetic studies to peptide and peptidomimetic cyclization. Curr Org Chem 2008;12:1502-1542.
11. Murphy PV. Peptidomimetics, glycomimetics and scaffolds from carbohydrate building blocks. 2007 July 08-13; Dublin, Ireland. Wiley-VCH Verlag Gmbh. p. 4177-4187.
12. Schmidt U, Guenther C, Rudolph R, Boehm G. Protein and peptide delivery via engineered polyomavirus-like particles. FASEB J 2001;15:1646-1648.
13. Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta-Rev Cancer 2008;1786:126-138.
14. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017.
15. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The 3rd helix of the antennapedia homeodomain translocates through biological membranes. J Biol Chem 1994;269:10444-10450.
16. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y. Arginine-rich peptides-An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 2001;276:5836-5840.
17. Damante G, Pellizzari L, Esposito G, Fogolari F, Viglino P, Fabbro D, Tell G, Formisano S, DiLauro R. A molecular code dictates sequence-specific DNA recognition by homeodomains. EMBO J 1996;15:4992-5000.
18. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the antennapedia homeodomain is receptor-independent. J Biol Chem 1996;271:18188-18193.
19. Prochiantz A, Chatelin L, Joliot A, Leroux I, Derossi D, Williams E, Doherty P, Volovitch M. Internalization and nuclear addressing of homeodomain-containing polypeptides by cells in culture. J Neurochem 1995;65:S7-S7.
20. Michael S, Thöle M, Dillmann R, Fahr A, Drewe J, Fricker G. Improvement of intestinal peptide absorption by a synthetic bile acid derivative, cholylsarcosine. Eur J Pharm Sci 2000;10:133-140.
21. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001;46:27-43.
22. Toth I. A novel chemical approach to drug delivery: Lipid amino acid conjugates. J Drug Target 1994;2:217-239.
23. Toth I, Hillery AM, Wood IP, Magnusson C, Artursson P. Oral absorption of lipidic amino-acid conjugates. Int J Pharm 1994;102:223-230.
24. Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A, Muranishi S. Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim Biophys Acta-Biomembr 1996;1283:119-126.
25. Bundgaard H, Hansen AB. Pro-drugs as drug delivery systems. Pharm Int 1981;2:136-140.
26. Testa B. Prodrugs: Bridging pharmacodynamic/pharmacokinetic gaps. Curr Opin Chem Biol 2009;13:338-344.
27. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Design 2009;15:2236-2250.
28. Kratz F, Müller Ivonne A, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem 2008;3:20-53.
29. Toth I, Flinn N, Hillery A, Gibbons WA, Artursson P. Lipidic conjugates of luteinizing hormone releasing hormone (LHRH) and thyrotropin releasing hormone (TRH) that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells. Int J Pharm 1994;105:241-247.
30. Flinn N, Coppard S, Toth I. Oral absorption studies of lipidic conjugates of thyrotropin releasing hormone (TRH) and luteinizing hormone-releasing hormone (LHRH). Int J Pharm 1996;137:33-39.
31. Flinn N, Hussain I, Shaw A, Artursson P, Gibbons WA, Toth I. Oral absorption studies of lipid-polylysine conjugates of thyrotropin releasing hormone (TRH) and luteinizing hormone releasing hormone (LHRH). Int J Pharm 1996;138:167-174.
32. Suzuki K, Susaki H, Okuno S, Yamada H, Watanabe HK, Sugiyama Y. Specific renal delivery of sugar-modified low-molecular-weight peptides. J Pharmacol Exp Ther 1999;288:888-897.
33. Koda Y, Del Borgo M, Wessling ST, Lazarus LH, Okada Y, Toth I, Blanchfield JT. Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides. Bioorg Med Chem 2008;16:6286-6296.
34. Bergeon JA, Chan YN, Charles BG, Toth I. Oral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation. Biopolymers 2008;90:633-643.
35. Nomoto M, Yamada K, Haga M, Hayashi M. Improvement of intestinal absorption of peptide drugs by glycosylation: Transport of tetrapeptide by the sodium ion-dependent D-glucose transporter. J Pharm Sci 1998;87:326-332.
36. Kellam B, Drouillat B, Dekany G, Starr MS, Toth I. Synthesis and in vitro evaluation of lipoamino acid and carbohydrate-modified enkephalins as potential antinociceptive agents. Int J Pharm 1998;161:55-64.
37. Toth I, Malkinson JP, Flinn NS, Drouillat B, Horvath A, Erchegyi J, Idei M, Venetianer A, Artursson P, Lazorova L, Szende B, Keri G. Novel lipoamino acid- and liposaccharide-based system for peptide delivery: Application for oral administration of tumor-selective somatostatin analogues. J Med Chem 1999;42:4010-4013.
38. Brewer JM. (How) do aluminium adjuvants work? Immunol Lett 2006;102:10-15.
39. Tang CK, Sheng KC, Apostolopoulos V, Pietersz GA. Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors. Expert Rev Vaccines 2008;7:1005-1018.
40. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IFC. Oxidative/reduction conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995;92:10128-10132.
41. Tang CK, Sheng KC, Esparon SE, Proudfoot O, Apostolopoulos V, Pietersz GA. Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier. Biomaterials 2009;30:1389-1400.
42. Schutze MP, Leclerc C, Jolivet M, Audibert F, Chedid L. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J Immunol 1985;135:2319-2322.
43. Tam JP. Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci USA 1988;85:5409-5413.
44. Simerska P, Abdel-Aal ABM, Fujita Y, Moyle PM, McGeary RP, Batzloff MR, Olive C, Good MF, Toth I. Development of a liposaccharide-based delivery system and its application to the design of group a streptococcal vaccines. J Med Chem 2008;51:1447-1452.
45. Jung G, Wiesmüller K-H, Becker G, Bühring H-J, Bessler WG. Increased production of specific antibodies by presentation of the antigen determinants with covalently coupled lipopeptide mitogens. Angewandte Chemie International Ed In English 1985;24:872-873.
46. Nardelli B, Tam JP. Cellular immune-responses induced by in-vivo priming with a lipid-conjugated multimeric antigen peptide. Immunology 1993;79:355-361.
47. Wiesmüller K-H, Bessler WG, Jung G. Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope-specific B-, T-helper and T-killer cell response. Int J Pept Prot Res 1992;40:255-260.
48. Toth I, Danton M, Flinn N, Gibbons WA. A combined adjuvant and carrier system for enhancing synthetic peptides immunogenicity utilizing lipidic amino acids. Tetrahedron Lett 1993;34:3925-3928.
49. Jackson DC, O'Brien-Simpson N, Ede NJ, Brown LE. Free radical induced polymerization of synthetic peptides into polymeric immunogens. Vaccine 1997;15:1697-1705.
50. Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PTP. A chimeric multi-human epidermal growth factor receptor-2 B-cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 2003;170:4242-4253.
51. Livingston BD, Newman M, Crimi C, McKinney D, Chesnut R, Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001;19:4652-4660.
52. Hu MC, Walls MA, Stroop SD, Reddish MA, Beall B, Dale JB. Immunogenicity of a 26-valent group A streptococcal vaccine. Infect Immun 2002;70:2171-2177.
53. Durier C, Launay O, Meiffrédy V, Saïdi Y, Salmon D, Lévy Y, Guillet JG, Pialoux G, Aboulker JP. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. AIDS 2006;20:1039-1049.
54. + T lymphocyte activation. Eur J Immunol 2000;30:3256-3265.
55. Déprez B, Gras-Masse H, Martinon F, Gomard E, Lévy J, Tartar A. Pimelautide or trimexautide as built-in adjuvants associated with an HIV-1-derived peptide: Synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response. J Med Chem 1995;38:459-465.
56. Deprez B, Sauzet J-P, Boutillon C, Martinon F, Tartar A, Sergheraert C, Guillet J-G, Gomard E, Gras-Masse H. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 1996;14:375-382.
57. Klinguer C, David D, Kouach M, Wieruszeski JM, Tartar A, Marzin D, Lévy JP, Gras-Masse H. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine 1999;18:259-267.
58. + T-cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type-1 lipopeptide vaccine. AIDS Res Hum Retrov 2006;22:684-694.
59. Gahéry-Ségard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Lévy JP, Gras-Masse H, Guillet J-G. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 2000;74:1694-1703.
60. +-T-cell epitopes recognized. J Virol 2003;77:11220-11231.
61. Pialoux G, Gahéry-Ségard H, Sermet S, Poncelet H, Fournier S, Gérard L, Tartar A, Gras-Masse H, Lévy JP, Guillet JG. Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 2001;15:1239-1240.
62. Lévy Y, Durier C, Lascaux AS, Meiffrédy V, Gahéry-Ségard H, Goujard C, Rouzioux C, Resch M, Guillet J-G, Kazatchkine M, Delfraissy J-F, Aboulker J-P. Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 2006;20:405-413.
63. Lévy Y, Gahéry-Ségard H, Durier C, Lascaux AS, Goujard C, Meiffrédy V, Rouzioux C, El Habib R, Beumont-Mauviel M, Guillet J-G, Delfraissy J-F, Aboulker J-P. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005;19:279-286.
64. BenMohamed L, Gras-Masse H, Tartar A, Daubersies P, Brahimi K, Bossus M, Thomas A, Druilhe P. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997;27:1242-1253.
65. Benmohamed L, Thomas A, Bossus M, Brahimi K, Wubben J, Gras-Masse H, Druilhe P. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 2000;18:2843-2855.
66. BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect Immun 2004;72:4376-4384.
67. + T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J Virol 1999;73:4447-4451.
68. Mortara L, Letourneur F, Villefroy P, Beyer C, Gras-Masse H, Guillet J-G, Bourgault-Villada I. Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge. Virology 2000;278:551-561.
69. Coutsinos Z, Villefroy P, Gras-Masse H, Guillet J-G, Bourgault-Villada I. Evaluation of SIV-lipopeptide immunizations administered by the intradermal route in their ability to induce antigen specific T-cell responses in rhesus macaques. FEMS Immunol Med Microbiol 2005;43:357-366.
70. Le Gal FA, Prevost-Blondel A, Lengagne R, Bossus M, Farace F, Chaboissier A, Gras-Masse H, Engelhard VH, Guillet JG, Gahery-Segard H. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study. Int J Cancer 2002;98:221-227.
71. ε-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity. Eur J Immunol 2004;34:3102-3114.
72. 1 responses and protect against ocular infection. J Virol 2005;79:15289-15301.
73. Silbermann B, Tod M, Desaint C, Pialoux G, Petitprez K, Slama L, Poncelet H, Moreau C, Mazarin V, Heshmati F, Salmon-Ceron D, Guillet JG, Launay O. Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers. AIDS Res Hum Retrov 2008;24:1445-1448.
74. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 2002;106:113-121.
75. Alexander J, del Guercio MF, Maewal A, Qiao L, Fikes J, Chesnut RW, Paulson J, Bundle DR, DeFrees S, Sette A. Linear PADRE T helper epitope and carbohydrate B-cell epitope conjugates induce specific high titer IgG antibody responses. J Immunol 2000;164:1625-1633.
76. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, Grey HM. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-761.
77. Bourel-Bonnet L, Bonnet D, Malingue F, Gras-Masse H, Melnyk O. Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation. Bioconjugate Chem 2003;14:494-499.
78. Bettahi I, Zhang X, Afifi RE, BenMohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol 2006;19:220-236.
79. Kreutz M, Ackermann U, Hauschildt S, Krause SW, Riedel D, Bessler W, Andreesen R. A comparative analysis of cytokine production and tolerance induction by bacterial lipopeptides, lipopolysaccharides and Staphyloccous aureus in human monocytes. Immunology 1997;92:396-401.
80. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, Takeda K, Akira S. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001;13:933-940.
81. Alexopoulou L, Thomas V, Schnare M, Lobet Y, Anguita J, Schoen RT, Medzhitov R, Fikrig E, Flavell RA. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat Med 2002;8:878-884.
82. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, Modlin RL, Akira S. Cutting edge: Role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-14.
83. Buwitt-Beckmann U, Heine H, Wiesmüller K-H, Jung G, Brock R, Akira S, Ulmer AJ. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur J Immunol 2005;35:282-289.
84. Buwitt-Beckmann U, Heine H, Wiesmüller KH, Jung G, Brock R, Akira S, Ulmer AJ. TLR1- and TLR6-independent recognition of bacterial lipopeptides. J Biol Chem 2006;281:9049-9057.
85. Schlecht S, Wiesmuller KH, Jung G, Bessler WG. Enhancement of protection against Salmonella infection in mice mediated by a synthetic lipopeptide analogue of bacterial lipoprotein in S. typhimurium vaccines. Zentralbl Bakteriol 1989;271:493-500.
86. Baier W, Masihi N, Huber M, Hoffmann P, Bessler WG. Lipopeptides as immunoadjuvants and immunostimulants in mucosal immunization. Immunobiology 2000;201:391-405.
87. Bessler WG, Suhr B, Buhring HJ, Muller CP, Wiesmuller KH, Becker G, Jung G. Specific antibodies elicited by antigen covalently linked to a synthetic adjuvant. Immunobiology 1985;170:239-244.
88. Wiesmüller K-H, Jung G, Hess G. Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine 1989;7:29-33.
89. Deres K, Schild H, Wiesmüller K-H, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature 1989;342:561-564.
90. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T cells. Eur J Immunol 1991;21:2649-2654.
91. Loleit M, Ihlenfeldt HG, Brunjes J, Jung G, Muller B, Hoffmann P, Bessler WG, Pierres M, Haas G. Synthetic peptides coupled to the lipotripeptide P3CSS induce in vivo B and T-helper cell responses to HIV-1 reverse transcriptase. Immunobiology 1996;195:61-76.
92. Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T-cell responses. Proc Natl Acad Sci USA 2004;101:15440-15445.
93. Ghosh S, Walker J, Jackson DC. Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus. Immunology 2001;104:58-66.
94. Mühlradt PF, Kie ß M, Meyer H, Süßmuth R, Jung G. Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration. J Exp Med 1997;185:1951-1958.
95. Mühlradt PF, Kie ß M, Meyer H, Süßmuth R, Jung G. Structure and specific activity of macrophage-stimulating lipopeptides from Mycoplasma hyorhinis. Infect Immun 1998;66:4804-4810.
96. Metzger J, Wiesmuller KH, Schaude R, Bessler WG, Jung G. Synthesis of novel immunologically active tripalmitoyl-S-glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations. Int J Pept Prot Res 1991;37:46-57.
97. Batzloff MR, Hartas J, Zeng W, Jackson DC, Good MF. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T-cell epitope, and a self-adjuvanting lipid protects mice from group a streptococcus challenge and reduces throat colonization. J Infect Dis 2006;194:325-330.
98. + T cells for long-term pulmonary protection against influenza. Eur J Immunol 2006;36:770-778.
99. Lau YF, Deliyannis G, Zeng W, Mansell A, Jackson DC, Brown LE. Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines. Int Immunol 2006;18:1801-1813.
100. Chua BY, Eriksson EM, Brown LE, Zeng W, Gowans EJ, Torresi J, Jackson DC. A self-adjuvanting lipopeptide-based vaccine candidate for the treatment of hepatitis C virus infection. Vaccine 2008;26:4866-4875.
101. Chua BY, Zeng W, Lau YF, Jackson DC. Comparison of lipopeptide-based immunocontraceptive vaccines containing different lipid groups. Vaccine 2007;25:92-101.
102. Zeng W, Gauci S, Ghosh S, Walker J, Jackson DC. Characterisation of the antibody response to a totally synthetic immunocontraceptive peptide vaccine based on LHRH. Vaccine 2005;23:4427-4435.
103. Gibbons WA, Hughes RA, Charalambous M, Christodoulou M, Szeto A, Aulabaugh AE, Mascagni P, Toth I. Lipidic peptides, I Synthesis, resolution and structural elucidation of lipidic amino acids and their homo- and hetero-oligomers. Liebigs Ann Chem 1990;12:1175-1183.
104. Hayman WA, Brandt ER, Relf WA, Cooper J, Saul A, Good MF. Mapping the minimal murine T-cell and B-cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. Int Immunol 1997;9:1723-1733.
105. Abdel-Aal AB, Batzloff MR, Fujita Y, Barozzi N, Faria A, Simerska P, Moyle PM, Good MF, Toth I. Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group a streptococcal vaccine candidates. J Med Chem 2008;51:167-172.
106. Moyle PM, Barozzi N, Wimmer N, Olive C, Good M, Toth I. Development of peptide vaccines against HPV-16 associated cervical cancer and group A streptococci. Biopolymers 2005;80:556-557.
107. Hayman WA, Toth I, Flinn N, Scanlon M, Good MF. Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology. Immunol Cell Biol 2002;80:178-187.
108. Zhong G, Toth I, Reid R, Brunham RC. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis. J Immunol 1993;151:3728-3736.
109. France LL, Piatti PG, Newman JFE, Toth I, Gibbons WA, Brown F. Circular dichroism, molecular modeling, and serology indicate that the structural basis of antigenic variation in foot-and-mouth disease virus is α-helix formation. Proc Natl Acad Sci USA 1994;91:8442-8446.
110. Horváth A, Olive C, Karpati L, Sun HK, Good M, Toth I. Toward the development of a synthetic group A streptococcal vaccine of high purity and broad protective coverage. J Med Chem 2004;47:4100-4104.
111. Horváth A, Olive C, Wong A, Clair T, Yarwood P, Good M, Toth I. Lipoamino acid-based adjuvant carrier system: Enhanced immunogenicity of group A streptococcal peptide epitopes. J Med Chem 2002;45:1387-1390.
112. Moyle PM, Hari Y, Huang N, Olive C, Good MF, Toth I. A technique for the synthesis of highly-pure, mono-epitopic, multi-valent lipid core peptide vaccines. Tetrahedron Lett 2007;48:4965-4967.
113. Moyle PM, McGeary RP, Blanchfield JT, Toth I. Mucosal immunisation: Adjuvants and delivery systems. Curr Drug Deliv 2004;1:385-396.
114. Moyle PM, Olive C, Ho MF, Good MF, Toth I. Synthesis of a highly pure lipid core peptide-based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 2006;49:6364-6370.
115. Olive C, Batzloff M, Horvath A, Clair T, Yarwood P, Toth I, Good MF. Group A streptococcal vaccine delivery by immunization with a self-adjuvanting M protein-based lipid core peptide construct. Indian J Med Res 2004;119:88-94.
116. Olive C, Batzloff M, Horváth A, Clair T, Yarwood P, Toth I, Good MF. Potential of lipid core peptide technology as a novel self-adjuvanting vaccine delivery system for multiple different synthetic peptide immunogens. Infect Immun 2003;71:2373-2383.
117. Olive C, Batzloff MR, Horváth A, Wong A, Clair T, Yarwood P, Toth I, Good MF. A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies. Infect Immun 2002;70:2734-2738.
118. Olive C, Ho M-F, Dyer J, Lincoln D, Barozzi N, Toth I, Good MF. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus. J Infect Dis 2006;193:1666-1676.
119. Olive C, Hsien K, Horvath A, Clair T, Yarwood P, Toth I, Good MF. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides. Vaccine 2005;23:2298-2303.
120. Olive C, Sun HK, Ho M-F, Dyer J, Horváth A, Toth I, Good MF. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. J Infect Dis 2006;194:316-324.
121. Moyle PM, Olive C, Ho MF, Pandey M, Dyer J, Suhrbier A, Fujita Y, Toth I. Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines. J Med Chem 2007;50:4721-4727.
122. Moyle PM, Olive C, Sun HK, Good M, Toth I. Development of vaccines for the treatment of HPV-16 associated cervical cancer. Clinical and Experimental Pharmacology and Physiology; 2004, 1-6 August; Brisbane, Queensland, Australia. Blackwell Publishing. p A54.
123. Simerska P, Lu H, Toth I. Synthesis of a Streptococcus pyogenes vaccine candidate based on the M protein PL1 epitope. Bio Med Chem Lett 2009;19:821-824.
124. Simerska P, Abdel-Aal AB, Fujita Y, Batzloff MR, Good MF, Toth I. Synthesis and in vivo studies of carbohydrate-based vaccines against group A streptococcus. Biopolymers 2008;90:611-616.
125. Tam JP, Lu Y-A. Coupling difficulty associated with interchain clustering and phase transition in solid phase peptide synthesis. J Am Chem Soc 1995;117:12058-12063.
126. Dawson PE, Muir TW, Clark-Lewis I, Kent SBH. Synthesis of proteins by native chemical ligation. Science 1994;266:776-779.
127. Fujita Y, Moyle PM, Hieu S, Simerska P, Toth I. Investigation toward multi-epitope vaccine candidates using native chemical ligation. Biopolymers 2008;90:624-632.
128. Moyle PM, Olive C, Good MF, Toth I. Method for the synthesis of highly pure vaccines using the lipid core peptide system. J Pept Sci 2006;12:800-807.
129. Moyle PM, Olive C, Ho M-F, Burgess M, Karpati L, Good MF, Toth I. Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation. J Org Chem 2006;71:6846-6850.
130. Moyle PM, Olive C, Ho M-F, Good MF, Toth I. Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation. J Med Chem 2006;49:6364-6370.
131. Engering AJ, Cella M, Fluitsma D, Brockhaus M, Hoefsmit ECM, Lanzavecchia A, Pieters J. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 1997;27:2417-2425.
132. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IFC. Ex vivo targeting of the macrophage mannose receptor generates anti-tumour CTL responses. Vaccine 2000;18:3174-3184.
133. Apostolopoulos V, McKenzie IFC. Role of the mannose receptor in the immune response. Curr Mol Med 2001;1:469-474.
134. Tindle RW, Fernando GJP, Sterling JC, Frazer IH. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991;88:5887-5891.
135. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-26.
136. Ouellette AJ, Satchell DP, Hsieh MM, Hagen SJ, Selsted ME. Characterization of luminal paneth cell alpha-defensins in mouse small intestine. Attenuated antimicrobial activities of peptides with truncated amino termini. J Biol Chem 2000;275:33969-33973.
137. Persing DH, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Baldridge JR. Toll-like receptor 4 agonists as vaccine adjuvants. In: Virgil EJC, O'Hagan DT, editors. Immunopotentiators in modern vaccines. Burlington, MA: Elsevier Academic Press; 2006. pp 93-108.
138. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, Persing DH. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Exp Opin Biol Ther 2004;4:1129-1138.
139. Johnson AG. Adjuvant action of bacterial endotoxins on the primary antibody response. In: Landy M, Braun W, editors. Bacterial endotoxins: Proceedings of a symposium held at the Institute of Microbiology of Rutgers, the State University with support from the National Science Foundation. New Brunswick, NJ: Rutgers University Press; 1964. pp 252-262.
140. Ulrich JT, Myers KR. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm Biotech 1995;6:495-524.
141. Martin M, Michalek SM, Katz J. Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-2507.
142. Baldridge JR, Yorgensen Y, Ward JR, Ulrich JT. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine 2000;18:2416-2425.
143. Doherty TM, Olsen AW, van Pinxteren L, Andersen P. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect Immun 2002;70:3111-3121.
144. VanCott TC, Kaminski RW, Mascola JR, Kalyanaraman VS, Wassef NM, Alving CR, Ulrich JT, Lowell GH, Birx DL. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 1998;160:2000-2012.
145. Egan MA, Chong SY, Hagen M, Megati S, Schadeck EB, Piacente P, Ma BJ, Montefiori DC, Haynes BF, Israel ZR, Eldridge JH, Staats HF. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 2004;22:3774-3788.
146. Childers NK, Miller KL, Tong G, Llarena JC, Greenway T, Ulrich JT, Michalek SM. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen. Infect Immun 2000;68:5509-5516.
147. Jiang Z-H, Budzynski WA, Skeels LN, Krantz MJ, Koganty RR. Novel lipid A mimetics derived from pentaerythritol: Synthesis and their potent agonistic activity. Tetrahedron 2002;58:8833-8842.
148. Jiang ZH, Bach MV, Budzynski WA, Krantz MJ, Koganty RR, Longenecker BM. Lipid A structures containing novel lipid moieties: Synthesis and adjuvant properties. Bio Med Chem Lett 2002;12:2193-2196.
149. Jiang ZH, Budzynski WA, Qiu D, Yalamati D, Koganty RR. Monophosphoryl lipid A analogues with varying 3-O-substitution: Synthesis and potent adjuvant activity. Carb Res 2007;342:784-796.
150. Johnson DA, Keegan DS, Sowell CG, Livesay MT, Johnson CL, Taubner LM, Harris A, Myers KR, Thompson JD, Gustafson GL, Rhodes MJ, Ulrich JT, Ward JR, Yorgensen YM, Cantrell JL, Brookshire VG. 3-O-Desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J Med Chem 1999;42:4640-4649.
151. Johnson DA, Sowell CG, Johnson CL, Livesay MT, Keegan DS, Rhodes MJ, Ulrich JT, Ward JR, Cantrell JL, Brookshire VG. Synthesis and biological evaluation of a new class of vaccine adjuvants: Aminoalkyl glucosaminide 4-phosphates (AGPs). Bio Med Chem Lett 1999;9:2273-2278.
152. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM, Reed SG. Taking toll: Lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002;10:S32-S37.
153. Baldridge JR, Cluff CW, Evans JT, Lacy MJ, Stephens JR, Brookshire VG, Wang R, Ward JR, Yorgensen YM, Persing DH, Johnson DA. Immunostimulatory activity of aminoalkyl glucosaminide 4-phosphates (AGPs): Induction of protective innate immune responses by RC-524 and RC-529. J Endotox Res 2002;8:453-458.
154. Fujita Y, Abdel-Aal ABM, Wimmer N, Batzloff MR, Good MF, Toth I. Synthesis and immunological evaluation of self-adjuvanting glycolipopeptide vaccine candidates. Bioorg Med Chem 2008;16:8907-8913.
155. Minchin RF, Orr RJ, Cronin AS, Puls RL. The pharmacology of gene therapy. Croat Med J 1999;40:381-391.
156. Fenske DB, MacLachlan I, Cullis PR. Long-circulating vectors for the systemic delivery of genes. Curr Opin Mol Ther 2001;3:153-158.
157. Rippe K, Mucke N, Langowski J. Superhelix dimensions of a 1868 base pair plasmid determined by scanning force microscopy in air and in aqueous solution. Nucleic Acids Res 1997;25:1736-1744.
158. Molas M, Gomez-Valades AG, Vidal-Alabro A, Miguel-Tura M, Bermudez J, Bartrons R, Perales JC. Receptor-mediated gene transfer vectors: Progress towards genetic pharmaceuticals. Curr Gene Ther 2003;3:468-485.
159. Simoes S, Filipe A, Faneca H, Mano M, Penacho N, Duezguenes N, Pedroso De Lima M. Cationic liposomes for gene delivery. Expert Opin Drug Delivery 2005;2:237-254.
160. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci 2000;21:99-103.
161. Ledley FD. Pharmaceutical approach to somatic gene therapy. Pharm Res (NY) 1996;113:1595-1614.
162. Lee ER, Marshall J, Siegel CS, Jiang CW, Yew NS, Nichols MR, Nietupski JB, Ziegler RJ, Lane MB, Wang KX, Wan NC, Scheule RK, Harris DJ, Smith AE, Cheng SH. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996;7:1701-1717.
163. Mahato RI, Rolland A, Tomlinson E. Cationic lipid-based gene delivery systems: Pharmaceutical perspectives. Pharm Res 1997;14:853-859.
164. Behr J-P. Gene transfer with synthetic cationic amphiphiles: Prospects for gene therapy. Bioconjugate Chem 1994;5:382-389.
165. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001;98:8786-8791.
166. Zhou L, Thakur CS, Molinaro RJ, Paranjape JM, Hoppes R, Jeang K-T, Silverman RH, Torrence PF. Delivery of 2-5A cargo into living cells using the Tat cell penetrating peptide: 2-5A-tat. Bioorg Med Chem 2006;14:7862-7874.
167. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-315.
168. Richard JP, Melikov K, Brooks H, Prevot P, Lebleu B, Chernomordik LV. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem 2005;280:15300-15306.
169. Cotten M, Langlerouault F, Kirlappos H, Wagner E, Mechtler K, Zenke M, Beug H, Birnstiel ML. Transferrin polycation-mediated introduction of DNA into human leukemic cells-Stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci USA 1990;87:4033-4037.
170. Kichler A, Leborgne C, Coeytaux E, Danos O. Polyethylenimine-mediated gene delivery: A mechanistic study. J Gene Med 2001;3:135-144.
171. Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML. Influenza virus hemagglutinin-HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin polylysine DNA complexes toward a synthetic virus-like gene transfer vehicle. Proc Natl Acad Sci USA 1992;89:7934-7938.
172. Moffatt S, Wiehle S, Cristiano RJ. A multifunctional PEI-based cationic polyplex for enhanced systemic p53-mediated gene therapy. Gene Ther 2006;13:1512-1523.
173. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: Implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003;31:2717-2724.
174. Bloomfield VA. DNA condensation. Curr Opin Struct Biol 1996;6:334-341.
175. Vijayanathan V, Thomas T, Thomas TJ. DNA nanoparticles and development of DNA delivery vehicles for gene therapy. Biochemistry 2002;41:14085-14094.
176. Sakthivel T, Toth I, Florence AT. Distribution of a lipidic 2.5nm diameter dendrimer carrier after oral administration. Paris, France: Elsevier Science; 1998. pp 51-55.
177. Sakthivel T, Toth I, Florence AT. Synthesis and physicochemical properties of lipophilic polyamide dendrimers. Pharm Res 1998;15:776-782.
178. Toth I, Sakthivel T, Wilderspin AF, Bayele H, O'Donnell M, Perry DJ, Pasi KJ, Lee CA, Florence AT. Novel cationic lipidic peptide dendrimer vectors-In vitro gene delivery. STP Pharma Sci 1999;9:93-99.
179. Shah DS, Sakthivel T, Toth I, Florence AT, Wilderspin AF. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int J Pharm 2000;208:41-48.
180. Bayele HK, Sakthivel T, O'Donell M, Pasi KJ, Wilderspin AF, Lee CA, Toth I, Florence AT. Versatile peptide dendrimers for nucleic acid delivery. J Pharm Sci 2005;94:446-457.
181. Florence AT, Wilderspin AF, Toth I, Sakthivel T, Bayele HK. School of Pharmacy, University of London, UK assignee. Cationic dendrimers and their use as macromolecular carriers. Application: WO patent 99-GB31892000016807. 2000 19990923.
182. Marano RJ, Toth I, Wimmer N, Brankov M, Rakoczy PE. Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: A long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. Gene Ther 2005;12:1544-1550.
183. Marano RJ, Wimmer N, Kearns PS, Thomas BG, Toth I, Brankov M, Rakoczy PE. Inhibition of in vitro VEGF expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. Exp Eye Res 2004;79:525-535.
184. Parekh HS, Marano RJ, Rakoczy EP, Blanchfield J, Toth I. Synthesis of a library of polycationic lipid core dendrimers and their evaluation in the delivery of an oligonucleotide with hVEGF inhibition. Bioorg Med Chem 2006;14:4775-4780.
185. Coles DJ, Yang S, Esposito A, Mitchell D, Minchin RF, Toth I. The synthesis and characterisation of a novel dendritic system for gene delivery. Tetrahedron 2007;63:12207-12214.
186. Yang S, Coles DJ, Esposito A, Mitchell DJ, Toth I, Minchin RF. Cellular uptake of self-assembled cationic peptide-DNA complexes: Multifunctional role of the enhancer chloroquine. J Controlled Release 2009;135:159-165.